The clinical application of this novel platform as a preventive vaccine for cancer has revealed its potential for modulating the immune system through the signaling pathway of type I interferon-r, involved with CD4+ and CD8+ T cell lineage and Toll-like receptors [12,13]. Here, CD8A is linked to cancer.